May 2019 TBC

Boston, USA

LinkedIn logo for website footerstwitter

Agenda
9769- Agenda Menu

Thursday 24th May, 2018

Day1 Day2

Day1 Day2

 

chris haqq Chris Haqq, Chief Scientific Officer, Atara Biotherapeutics  09.00   Chair’s Opening Remarks
Identify Optimal Treg Populations With Increased Functional Capacity
Rosa Bacchetta Rosa Bacchetta,Associate Professor of Research, Pediatrics, Stem
Cell Transplantation, Stanford School of Medicine
09.10 LV- Mediated Gene Transfer to Generate T-regulatory Cells Suitable for Immunotherapy

Qizhi Tang Qizhi Tang, Professor and
Director, UCSF Transplantation Research Lab, Department of
Surgeryy, University of
California, San Francisco
09.40 Clinical Trials of Treg Cell Therapy in Transplantation

 10.10  Morning Refreshments and Speed Networking
Explore The Limitations Translating Outcomes from Animal Models into Human Disease
Kean_Leslie Leslie Kean, Associate Professor of Pediatrics, University of
Washington
11.10 Building an Optimal Treg Product: Lessons from NHP Studies

11.40 Panel Discussion: Animal Models and Beyond into the Clinic: Translating a Proof of Concept in Autoimmune Therapies
Stephen Miller, PhD, Immunology, FSM Stephen Miller, Professor at Northwestern University Feinberg School of Medicine & Co-founder,
Consultant and member of the Scientific Advisory Board, Cour Pharmaceutical
David Wraith David Wraith, Director of the Institute of Immunology and Immunotherapy, University of Birmingham & Chief Scientific Officer, Apitope International NV
Kean_Leslie Leslie Kean, Associate Professor of Pediatrics, University of
Washington
chris haqq Chris Haqq, Chief Scientific Officer, Atara Biotherapeutics

 12.10  Lunch and Networking
Discussion Session to Support the Discovery and Clinical Development of Treg Directed Therapies
 13.10 Round table Discussion
 14.10  Afternoon Refreshments
Comparison of Trafficking Approaches to Achieve Antigen Specific Tolerance
Andrew Scharenberg Andrew Scharenberg, Chief Scientific Officer, Casebia
Therapeutics
14.40 Engineering Regulatory T-cells for Inflammatory Disorders

Todd Brusko Todd Brusko, Associate Professor, Diabetes Instituter, University of Florida 15.10 Therapeutic Applications of Cord Blood-Derived Tregs for the Treatment of Type 1 Diabetes

stephane_floissel-200x200 Stephane Boissel, Chief Executive Officer, TxCell 15.40 Engineered Tregs for Autoimmunity, Inflammation and Transplantation

stephane_floissel-200x200  Chris Haqq, Chief Scientific Officer, Tolerance
Lead, Atara Biotherapeutics 
16.10 Encouraging Safety and Efficacy From Pioneering T-Cell Immunotherapy Clinical Studies in Autoimmune Disease

stephane_floissel-200x200 Kady Helme,Patient Advocate, JDRF 16.40 Living with Type 1 Diabetes
 stephane_floissel-200x200  Chris Haqq, Chief Scientific Officer, Tolerance
Lead, Atara Biotherapeutics 
17.00 Chair’s Closing Remarks

 17.05  End of Day 2

Event Guide_Treg